Definitive re-irradiation using intensity-modulated radiation therapy in cancers of the head and neck, focusing on rare tumors

Doi, Hiroshi; Uemoto, Kenji; Masai, Norihisa; Tatsumi, Daisaku; Shiomi, Hiroya; Oh, Ryoong‐Jin

doi:10.1080/00016489.2018.1438662

Cited by 7 publications

(6 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The two-year overall survival rates for recurrent/locally advanced SCC and non-SCC were 58% and 100%, respectively. There are a few reirradiation series for external auditory canal malignancies [13,22]. Our data also implied poorer outcome of SCC than non-SCC.…”

Section: Auditory Organ Cancermentioning

confidence: 55%

Reirradiation for Rare Head and Neck Cancers: Orbit, Auditory Organ, and Salivary Glands

Yamazaki¹,

Suzuki²,

Aibe³

et al. 2022

Cureus

Self Cite

View full text Add to dashboard Cite

We analyzed the efficacy and toxicity following reirradiation for locoregional recurrence of rare head and neck tumors. We retrospectively analyzed 17 patients who had received reirradiation for rare head and neck tumors. Primary tumor sites included nine ears (auditory organ), four salivary glands, and four orbits. The median follow-up time was 13.2 months for surviving patients. The median survival time was 12.6 months with one-and two-year survival rates of 53.1% and 44.3%, respectively. Nine out of 17 patients experienced local failure. The one-and two-year local control rates were 42.4% and 31.8%, respectively. The median survival times were 12.6, 5.3, and 11.0 months for orbit, auditory organ, and salivary glands, respectively. Three patients experienced grade 3 toxicity, including meningitis, brain necrosis, and facial nerve disorders. No grade ≥4 toxicities were observed. Reirradiation of rare head and neck tumors is feasible, with acceptable toxicity.

show abstract

Section: Auditory Organ Cancermentioning

confidence: 55%

Reirradiation for Rare Head and Neck Cancers: Orbit, Auditory Organ, and Salivary Glands

Yamazaki¹,

Suzuki²,

Aibe³

et al. 2022

Cureus

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, advanced radiotherapy, IMRT, image-guided radiotherapy, and stereotactic radiotherapy (SBRT) allow the application of high doses to complex volumes while sparing the surrounding organs at risk, with low toxicity [ 13 , 14 ]. Several authors have reported their reirradiation experiences with IMRT or SBRT in <10 patients [ 14 , 20 , 21 ]. Iwata et al [ 9 ] reported the treatment results of 51 patients with locally recurrent nasal and paranasal carcinoma using CyberKnife with a prescribed median dose of 35 Gy (range, 20–41.5 Gy) in 3–5 fractions.…”

Section: Discussionmentioning

confidence: 99%

Reirradiation for Nasal Cavity or Paranasal Sinus Tumor—A Multi-Institutional Study

Yamazaki

Suzuki

Aibe

et al. 2021

Cancers

Self Cite

View full text Add to dashboard Cite

We evaluated the efficacy and toxicity of reirradiation of nasal cavity or paranasal sinus tumors. We collected and analyzed multi-institutional data of reirradiation cases. Seventy-eight patients with nasal or paranasal sinus tumors underwent reirradiation. The median survival time was 20 months with a medial follow-up of 10.7 months. The 2-year local control and overall survival rates were 43% and 44%, respectively. Tumor volume (≤25 cm3), duration between previous radiotherapy and reirradiation (≤12 months), histology (squamous cell carcinoma), male sex, and lymph node involvement were predisposing factors for poor survival. Distant metastasis was observed in 20 patients (25.6%). Grade ≥ 3 adverse events were observed in 22% of the patients, including five grade 4 (8.6%) cases and one grade 5 (1.2%) case. Tumor location adjacent to the optic pathway was a significant predisposing factor for grade ≥3 visual toxicity. Reirradiation of nasal and paranasal sinus tumors is feasible and effective. However, adverse events, including disease-related toxicities, were significant. Prognostic factors emerge from this study to guide multidisciplinary approaches and clinical trial designs.

show abstract

“…In recent years, IMRT has been widely used in the treatment of various head and neck tumours, including NPC and other rare cancers. 19 , 20 In addition, a clinical study reported that IMRT not only significantly improved treatment outcomes but also reduced the incidence of some side effects. 21 Intensity-modulated radiation allows the clinician to adjust the intensity of each radiation according to the actual situation, so each beam field can have one or more high-intensity radiation areas and any number of low-intensity areas within the same field, thus allowing greater control over the dose distribution with the target.…”

Section: Methodsmentioning

confidence: 99%

Development of a Radiotherapy Localisation Computed Tomography-Based Radiomic Model for Predicting Survival in Patients With Nasopharyngeal Carcinoma Treated With Intensity-Modulated Radiotherapy Following Induction Chemotherapy

Chen

Zhao

et al. 2022

Cancer Control

View full text Add to dashboard Cite

Background Our purpose is to develop a model combining radiomic features of radiotherapy localisation computed tomography and clinical characteristics that can be used to estimate overall survival in patients with nasopharyngeal carcinoma treated with intensity-modulated radiotherapy following induction chemotherapy. Methods We recruited 145 patients with pathologically confirmed nasopharyngeal carcinoma between February 2012 and April 2015. In total, 851 radiomic features were extracted from radiotherapy localisation computed tomography images for the gross tumour volume of the nasopharynx and the gross tumour volume of neck metastatic lymph nodes. The least absolute shrinkage and selection operator algorithm was applied to select radiomics features, build the model and calculate the Rad-score. The patients were divided into high- and low-risk groups based on their Rad-scores. A nomogram for estimating overall survival based on both radiomic and clinical features was generated using multivariate Cox regression hazard models. Prediction reliability was evaluated using Harrell’s concordance index. Results In total, seven radiomic features and one clinical characteristic were extracted for survival analysis, and the combination of radiomic and clinical features was a better predictor of overall survival (concordance index = .849 [confidence interval: .782-.916]) than radiomic features (concordance index = .793 [confidence interval: .697-.890]) or clinical characteristics (concordance index = .661 [confidence interval: .673-.849]) alone. Conclusion Our results show that a nomogram combining radiomic features of radiotherapy localisation computed tomography and clinical characteristics can predict overall survival in patients with nasopharyngeal carcinoma treated with intensity-modulated radiotherapy following induction chemotherapy more effectively than radiomic features or clinical characteristics alone.

show abstract

Definitive re-irradiation using intensity-modulated radiation therapy in cancers of the head and neck, focusing on rare tumors

Abstract: Re-irradiation of rare head and neck tumors using IMRT for loco-regional recurrence may be an acceptable treatment option.

Cited by 7 publications

References 16 publications

Reirradiation for Rare Head and Neck Cancers: Orbit, Auditory Organ, and Salivary Glands

Reirradiation for Rare Head and Neck Cancers: Orbit, Auditory Organ, and Salivary Glands

Reirradiation for Nasal Cavity or Paranasal Sinus Tumor—A Multi-Institutional Study

Development of a Radiotherapy Localisation Computed Tomography-Based Radiomic Model for Predicting Survival in Patients With Nasopharyngeal Carcinoma Treated With Intensity-Modulated Radiotherapy Following Induction Chemotherapy

Contact Info

Product

Resources

About